Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

152 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial.
Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Lassman AB, et al. Among authors: bain e. Neuro Oncol. 2019 Jan 1;21(1):106-114. doi: 10.1093/neuonc/noy091. Neuro Oncol. 2019. PMID: 29982805 Free PMC article. Clinical Trial.
Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial.
Lassman AB, Pugh SL, Wang TJC, Aldape K, Gan HK, Preusser M, Vogelbaum MA, Sulman EP, Won M, Zhang P, Moazami G, Macsai MS, Gilbert MR, Bain EE, Blot V, Ansell PJ, Samanta S, Kundu MG, Armstrong TS, Wefel JS, Seidel C, de Vos FY, Hsu S, Cardona AF, Lombardi G, Bentsion D, Peterson RA, Gedye C, Bourg V, Wick A, Curran WJ, Mehta MP. Lassman AB, et al. Among authors: bain ee. Neuro Oncol. 2023 Feb 14;25(2):339-350. doi: 10.1093/neuonc/noac173. Neuro Oncol. 2023. PMID: 35849035 Free PMC article. Clinical Trial.
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study.
van den Bent M, Gan HK, Lassman AB, Kumthekar P, Merrell R, Butowski N, Lwin Z, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Bain E, Ansell PJ, Holen KD, Maag D, Reardon DA. van den Bent M, et al. Among authors: bain e. Cancer Chemother Pharmacol. 2017 Dec;80(6):1209-1217. doi: 10.1007/s00280-017-3451-1. Epub 2017 Oct 26. Cancer Chemother Pharmacol. 2017. PMID: 29075855 Free PMC article. Clinical Trial.
Epidermal growth factor receptor (EGFR) amplification rates observed in screening patients for randomized trials in glioblastoma.
Lassman AB, Aldape KD, Ansell PJ, Bain E, Curran WJ, Eoli M, French PJ, Kinoshita M, Looman J, Mehta M, Muragaki Y, Narita Y, Ocampo C, Roberts-Rapp L, Song M, Vogelbaum MA, Walenkamp AME, Wang TJC, Zhang P, van den Bent MJ. Lassman AB, et al. Among authors: bain e. J Neurooncol. 2019 Aug;144(1):205-210. doi: 10.1007/s11060-019-03222-y. Epub 2019 Jul 4. J Neurooncol. 2019. PMID: 31273577 Free PMC article. Clinical Trial.
An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR.
Mittapalli RK, Stodtmann S, Friedel A, Menon RM, Bain E, Mensing S, Xiong H. Mittapalli RK, et al. Among authors: bain e. J Clin Pharmacol. 2019 Sep;59(9):1225-1235. doi: 10.1002/jcph.1418. Epub 2019 Apr 16. J Clin Pharmacol. 2019. PMID: 30990907 Clinical Trial.
Defining EGFR amplification status for clinical trial inclusion.
French PJ, Eoli M, Sepulveda JM, de Heer I, Kros JM, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Weller M, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, van den Bent M. French PJ, et al. Among authors: bain e. Neuro Oncol. 2019 Oct 9;21(10):1263-1272. doi: 10.1093/neuonc/noz096. Neuro Oncol. 2019. PMID: 31125418 Free PMC article.
EGFR mutations are associated with response to depatux-m in combination with temozolomide and result in a receptor that is hypersensitive to ligand.
Hoogstrate Y, Vallentgoed W, Kros JM, de Heer I, de Wit M, Eoli M, Sepulveda JM, Walenkamp AME, Frenel JS, Franceschi E, Clement PM, Weller M, van Royen ME, Ansell P, Looman J, Bain E, Morfouace M, Gorlia T, Golfinopoulos V, van den Bent M, French PJ. Hoogstrate Y, et al. Among authors: bain e. Neurooncol Adv. 2019 Dec 9;2(1):vdz051. doi: 10.1093/noajnl/vdz051. eCollection 2020 Jan-Dec. Neurooncol Adv. 2019. PMID: 32642719 Free PMC article.
Mitigating the Effects of Nonadherence in Clinical Trials.
Shiovitz TM, Bain EE, McCann DJ, Skolnick P, Laughren T, Hanina A, Burch D. Shiovitz TM, et al. Among authors: bain ee. J Clin Pharmacol. 2016 Sep;56(9):1151-64. doi: 10.1002/jcph.689. Epub 2016 Jan 22. J Clin Pharmacol. 2016. PMID: 26634893 Free PMC article.
152 results